shift in cellular properties toward an activated state, and their relevance to host response mechanisms is emphasized by the association of JE/MCP-1 expression with recruitment of MPs into tissues. The latter conclusion is supported by results of studies in transgenic models with targeted expression of JE/MCP-1 expression 30 -32 and experiments in JE/MCP-1-deficient mice, 33 as well as correlative work (see Reference 8) and studies with blocking antibodies. 34 In the context of atherosclerotic vascular disease, there is compelling evidence for a pathogenic role of JE/MCP-1. Expression of JE/MCP-1 has been noted in cell types critical to the formation of such vascular lesions, including endothelium, MPs, and smooth muscle. Experiments with mice rendered genetically deficient in JE/MCP-1 or its key target receptor, CCR2, have shown diminished formation of atherosclerotic lesions. 11, 35 Bone marrow transplantation with cells from mice overexpressing a JE/MCP-1 transgene into apolipoprotein E-null animals resulted in repopulation of the bone marrow with cells bearing the transgene, along with increased lesion formation, oxidized lipids, and macrophage infiltration. 9 The observed elevation of JE/MCP-1 in patients with acute myocardial infarction 13 draws this chemokine into the biology of acute events associated with plaque rupture and vascular wall remodelling. These observations are consistent with the results of studies in a canine model of myocardial ischemia/reperfusion, in which JE/MCP-1 expression was noted within an hour of the ischemic insult. 36 As a member of the group of "immediate-early" genes whose expression occurs with a rapid time course after exposure to stimuli, 37 the brief interval between injury to the vessel wall (ie, angioplasty) and expression of JE/MCP-1 might have been predicted. In a model of balloon injury to normal rabbit aortas, upregulation of JE/MCP-1 transcripts was noted by 1 hour and reached a maximum by 4 hours, returning to baseline by 8 hours. 38 In view of the absence of invading MPs during these early times (1 to 4 hours) and the completeness of endothelial denudation, the authors concluded that vascular SMCs were the likely source of JE/ MCP-1. These data are consistent with subsequent results in a rat carotid injury model in which early expression of JE/MCP-1 was noted, and administration of neutralizing polyclonal antibody to JE/MCP-1 with different regimens during the first 5 days was associated with diminished neointimal expansion. 39 In a porcine iliac artery angioplasty model, early expression of JE/MCP-1 transcripts (by 2 hours) was also observed. 40 JE/MCP-1 expression was maximal in the latter model at 8 hours and declined to baseline by 16 to 24 hours. Immunohistochemical analysis of the site of injury performed at 8 hours demonstrated JE/MCP-1 to be predominately associated with MPs. Putting together these observa-tions, it would be predicted that induction of JE/MCP-1 transcripts occurs at the earliest stages after vascular injury in vascular SMCs, and shortly thereafter, in infiltrating MPs.
The observations of Cipollone et al 3 suggest an important addition to this view of JE/MCP-1 and the biology of restenosis accompanying angioplasty. In a study of 50 patients undergoing PTCA, the authors observed that patients with restenosis had statistically significant elevations in plasma MCP-1 compared with nonrestenotic patients (mea apolipoprotein E-deficient (apoE -/-) mice. Previous studies sured at 1, 5, 15, and 180 days). In contrast, 2 other chemokines, regulated on activation normally T cell expressed and secreted and interleukin-8, did not follow a similar pattern. There was no difference in baseline levels of JE/MCP-1 in patients who would/would not develop restenosis. Based on multivariate regression analysis, MCP-1 plasma levels at 15 days after angioplasty proved to be a significant independent predictor of restenosis. Two important caveats related to this study, in terms of extrapolation to the larger general population of patients undergoing angioplasty, concern (1) the exclusion of patients who underwent stenting after PTCA from the study and (2) the relatively small number of patients evaluated. However, despite these limitations, this work raises important issues for future study.
In contrast to the previous focus on early expression of JE/MCP-1 after angioplasty in animals with normal vasculature, the data of Cipollone et al 3 suggest that in human arteries with underlying atherosclerosis, induction of JE/MCP-1 may be more sustained. There are several mechanisms that could underlie these observations, such as prolonged activation of nuclear factor-B and Egr-1 in the injured vessel wall. [41] [42] [43] [44] In addition, a role for peroxisome proliferator-activated receptor-␣, 45 platelet-derived growth factor, 38, 46 and/or diminished local nitric oxide production 47, 48 might be involved in the second phase of JE/MCP-1 expression. However, the key point is that one can surmise a positive feedback loop in which mechanisms that would ordinarily limit JE/MCP-1 to a brief pulse (coincident with expression of other chemokines) early after injury of the normal vessel wall have been supplanted by a more sustained stimulus in which JE/MCP-1 expression is potentiated (Fig. 1) . Such prolonged JE/MCP-1 production could have autocrine/paracrine effects on MPs and SMCs at the site of the lesions and would be reflected in the apparent activation of MPs observed in patients with increased levels of JE/MCP-1. 3 Viewed in this context, the observations of Cipollone and colleagues 3 provide a potential opportunity to translate results from animal models and clinical observations to therapeutic concepts. At the very least, plasma levels of JE/MCP-1 provide a valuable index of MP activation after angioplasty and are likely to be reflective of events occurring locally in the injured vessel wall. If this extrapolation proves to be valid at the level of pathogenesis of vascular lesions, then interception of the interaction of JE/MCP-1 with its receptor could provide a future therapeutic modality for patients at risk for restenosis. 
